Literature DB >> 21868209

Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease.

Mauli Mehta1, Theodore K Marras.   

Abstract

INTRODUCTION: The impact of pulmonary nontuberculous mycobacterial (pNTM) disease on health-related quality of life (HRQL) has not been quantified.
METHODS: We performed a prospective observational study of HRQL in 51 patients with pNTM disease. One generic (Short-form 36, version 2 -SF-36), and one pulmonary disease-specific instrument (St. George's Respiratory Questionnaire--SGRQ) were administered to each subject.
RESULTS: Fifty-one patients with pNTM disease from one ambulatory clinic were enrolled. The mean (sd) age was 67 (10) years and 80% (41/51) were female. The most common causative NTM was MAC in 84% (43/51) followed by Mycobacterium abscessus in 8% (4/51). Radiographic disease type was nodular bronchiectasis in 71% (36/51) and fibrocavitary in 22% (11/51). For SF-36, most raw scores were at least 10 points below Canadian population-based normals, and all normbased scores were below the expected normal value of 50. For SGRQ, all scores were worse by ≥ 25 points compared with published normals. In multivariable analyses, only FVC and DLCO were significantly associated with SF-36, and only FVC and emphysema were significantly associated with SGRQ.
CONCLUSION: Patients with pNTM disease have significantly impaired HRQL that is most closely associated with lung function and not readily explained by age, sex or extra-pulmonary comorbidity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21868209     DOI: 10.1016/j.rmed.2011.08.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  25 in total

Review 1.  Surgical management of non-cystic fibrosis bronchiectasis.

Authors:  Miyako Hiramatsu; Yuji Shiraishi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Vincent X Liu; Kevin L Winthrop; Yun Lu; Husham Sharifi; Hekmat U Nasiri; Stephen J Ruoss
Journal:  Ann Am Thorac Soc       Date:  2018-10

3.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Authors:  Kenneth N Olivier; David E Griffith; Gina Eagle; John P McGinnis; Liza Micioni; Keith Liu; Charles L Daley; Kevin L Winthrop; Stephen Ruoss; Doreen J Addrizzo-Harris; Patrick A Flume; Daniel Dorgan; Matthias Salathe; Barbara A Brown-Elliott; Renu Gupta; Richard J Wallace
Journal:  Am J Respir Crit Care Med       Date:  2017-03-15       Impact factor: 21.405

4.  Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease.

Authors:  Ji Young Hong; Sang A Lee; Song Yee Kim; Kyung Soo Chung; Sung Woo Moon; Eun Young Kim; Ji Ye Jung; Moo Suk Park; Young Sam Kim; Se Kyu Kim; Joon Chang; Young Ae Kang
Journal:  Qual Life Res       Date:  2014-06-08       Impact factor: 4.147

5.  Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.

Authors:  Takuya Ozawa; Ho Namkoong; Risako Takaya; Yusuke Takahashi; Koichi Fukunaga; Yuki Enoki; Kazuaki Taguchi; Junko Kizu; Kazuaki Matsumoto; Naoki Hasegawa
Journal:  BMC Infect Dis       Date:  2022-06-29       Impact factor: 3.667

6.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

7.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

8.  The impact of bronchial artery embolisation on the quality of life of patients with haemoptysis: a prospective observational study.

Authors:  Naoki Omachi; Hideo Ishikawa; Masahiko Hara; Takashi Nishihara; Yu Yamaguchi; Yumiko Yamamoto; Mihoko Youmoto; Tomoaki Hattori; Kazushi Kitaguchi; Shota Yamamoto; Tomoya Kawaguchi; Masahiro Fukuzawa
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

9.  Effects of pain on depression, sleep, exercise tolerance, and quality of life in patients with nontuberculous mycobacterial pulmonary disease.

Authors:  Kosuke Mori; Mitsuru Tabusadani; Kazumasa Yamane; Satoshi Takao; Yuki Kuroyama; Yusuke Matsumura; Kazuki Ono; Kazuma Kawahara; Shunya Omatsu; Keiji Fujiwara; Koji Furuuchi; Kozo Morimoto; Hiroshi Kimura; Hideaki Senjyu
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

10.  Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease.

Authors:  Meng-Rui Lee; Ching-Yao Yang; Kai-Ping Chang; Li-Ta Keng; David Hung-Tsang Yen; Jann-Yuan Wang; Huey-Dong Wu; Li-Na Lee; Chong-Jen Yu
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.